I guess my question is that Joe said they were waiting on a last valuation for NGIO. I get that. But the deals they are making / have made. If wording says (Generex), how can NGIO have valuation on deals that have wording stated as Generex and not to NGIO? Seems the valuation would need to be Generex instead, since the deals fall under the Generex umbrella unless I am reading this wrong.
Wouldn't Generex have the lion share of the valuation due to being named in the deal? Maybe my logic is wrong here.
(0)
(0)
Generex Biotechnology Corp. (GNBTQ) Stock Research Links